TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05815173
Drug: Ladarixin
Normalized name: Ladarixin
DrugBank: Ladarixin (DB16212)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ladarixin dose will be escalated as follows in Phase I: 3 patients will receive a starting dose of 200mg. If 2 or more patients experience a DLT at the lowest dose, the study will stop. If 0 out of 3 patients experience a DLT within 28 days, the next 3 patients will receive 300mg. If 1 out of 3 patients experiences a DLT, 3 more patients will be added to the 200 mg dose. If no more patients experience a DLT at 200mg, the next 3 patients will receive 300mg. If 2 of 6 patients receiving 200mg experience a DLT, the study will stop. If 2 or more patients experience DLTs, the maximum tolerated dose (MTD) will be the previous dose level. The same process will be repeated at each dose level. There will be 6 patients enrolled at MTD level for a maximum of 12 patients in the phase I cohort. Ladarixin will be administered as a twice-daily dose over a 21 day treatment cycle.~In Phase II, ladarixin will be administered twice-daily at the recommended phase II dose over 21-day cycles.
Study: NCT06137170
Drug: Regorafenib (Stivarga, BAY73-4506)
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Follow clinical administration.
Study: NCT05479812
Drug: pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Investigation Product in combination with approved therapy
Study: NCT04562389
Drug: Selinexor
Normalized name: Selinexor
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will receive a dose of 40 or 60 mg selinexor oral tablets QW.
Study: NCT04562389
Drug: Selinexor
Normalized name: Selinexor
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will receive a dose of 60 mg selinexor oral tablets QW.
Study: NCT04562389
Drug: Ruxolitinib
Normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive a dose of 15 or 20 mg ruxolitinib oral tablets BID.
Study: NCT04912258
Drug: Trans arterial chemoembolization with Irinotecan Drug-eluting Beads
Normalized name: ketotifen fumarate 0.019 mg INTRAOCULAR drug-eluting contact lens [ACUVUE Theravision with Ketotifen]
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: preoperative chemoembolization with Irinotecan Drug-eluting Beads
Study: NCT06305182
Drug: Metreleptin
Normalized name: Metreleptin
DrugBank: Metreleptin (DB09046)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metreleptin 3 mg is packaged in 3 ml Type I glass vials with chlorobutyl rubber stoppers, and aluminum seals with plastic flip-off caps. The vials are stored in refrigerator (2 - 8°C) and protected from light. Metreleptin for injection is a sterile, white, solid lyophilised cake.~Prior to patient use, the content of a vial is reconstituted with 0.6 ml of water for injection for a final formulation of 10 millimolar (mM) glutamic acid, 2% glycine, 1% sucrose, 0.01% polysorbate 20, potential hydrogen (pH) 4.25. The resulting solution is administered by subcutaneous injection.
Study: NCT06305182
Drug: Sodium chloride
Normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The placebo will consist of sterile 0.9% saline (Sodium chloride), drawn up from a 10 ml i.v. vials. The placebo will be administered as an subcutaneous injection in an identical procedure as the metreleptin verum.
Study: NCT05140525
Drug: Macitentan Tablets
Normalized name: Macitentan Tablets
DrugBank: Macitentan (DB08932)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 10 mg oral once daily
Study: NCT05140525
Drug: Riociguat
Normalized name: Riociguat
DrugBank: Riociguat (DB08931)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 mg to 2.5mg oral three times daily
Study: NCT06086171
Drug: Methadone Hydrochloride
Normalized name: Methadone Hydrochloride
DrugBank: Methadone (DB00333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methadone hydrochloride (0.10 mg/kg) administered intravenously at the induction of anaesthesia
Study: NCT05186818
Drug: Aficamten (5 mg, 10 mg, 15 mg, and 20 mg)
Normalized name: Aficamten
DrugBank: Aficamten (DB18490)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aficamten tablets were administered orally once daily.
Study: NCT05186818
Drug: Placebo to match aficamten
DrugBank: Fica (DB03384)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets were administered orally once daily.
Study: NCT06634030
Drug: RhPDGF-BB
Normalized name: rhPDGF-BB
DrugBank: Becaplermin (DB00102)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.3 mg/mL rhPDGF-BB
Study: NCT06634030
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Normal saline
Study: NCT05757492
Drug: CHS-006 (anti-TIGIT)
Normalized name: anti-CD11a
DrugBank: Efalizumab (DB00095)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Arm A participants will receive CHS-006 administered via IV Q3W.
Study: NCT05757492
Drug: toripalimab (anti-PD-1)
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm B participants will receive toripalimab administered via IV Q3W.
Study: NCT06253520
Drug: Aldesleukin
Normalized name: Aldesleukin
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aldesleukin 600,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 10 doses). Patients in Cohort 3 may receive 72,000 IU/kg IV.
Study: NCT06253520
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Days -7 to -3: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.
Study: NCT06558214
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Keytruda® is the trade name for pembrolizumab, which will be given as 200mg IV Q3 weeks. This treatment will continue for up to two years.
Study: NCT04659031
Drug: ABC008
Normalized name: Immunoglobulin G1, anti-(human killer cell lectin-like receptor subfamily G member 1) (human-Mus musculus monoclonal ABC008 γ1-chain), disulfide with human-Mus musculus monoclonal ABC008 κ-chain, dime
DrugBank: Ulviprubart (DB18281)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABC008
Study: NCT06024096
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin is a lipid-lowering agent of the statin family that functions by blocking a rate-limiting enzyme, Hydroxymethylglutaryl-CoA (HMG-CoA) reductase, in lipid metabolism. This agent is commonly used for primary and secondary prevention of dyslipidemia. Participants will be asked to take Atorvastatin 80 mg daily at night, for 4 weeks prior to the vaccination, and continue the statin therapy for 4 weeks after vaccination.~The 80mg dose of atorvastatin allows for evaluation of the immunologic effects of statin medication with a short duration of therapy prior to vaccination.
Study: NCT05581030
Drug: Calaspargase Pegol
Normalized name: Calaspargase pegol
DrugBank: Calaspargase pegol (DB14730)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calaspargase pegol 2000 IU/m\^2 (capped at 3750 IU) will be administered beginning in cycle 1B of Hyper-CVAD, and will continue at this dose for the duration of the trial.
Study: NCT05581030
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab 375mg/m\^2 will be administered once per cycle for patients with CD20+ ALL.
Study: NCT05220514
Drug: 2-(4-[11C]methylamino phenyl)-6-hydroxybenzothiazole (11C]6-OH-BTA-1 or [11C]PIB)
Normalized name: 11C-choline
DrugBank: Choline C 11 (DB09277)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotracer used during the PET-MR scan of the study to identify signs of disease. Used in studies related to Alzheimer's disease. Only FDA approved for investigational use.
Study: NCT05136404
Drug: Selpercatinib
Normalized name: Selpercatinib
DrugBank: Selpercatinib (DB15685)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered orally
Study: NCT05114941
Drug: intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin treatment regimen: intravenous immunoglobulin therapy, 400mg/kg/d, once a day, for at least 5 consecutive days.
Study: NCT06405607
Drug: Psilocybin
Normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg single dose
Study: NCT06405607
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.75 mg/kg weight-based single dose
Study: NCT05847920
Drug: SHR-2010 Injection
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-2010 Injection
Study: NCT01236287
Drug: Voclosporin
Normalized name: Voclosporin
DrugBank: Voclosporin (DB11693)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive voclosporin capsules, twice daily
Study: NCT06203821
Drug: NP137
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: NP137 for the Treatment of Resectable Pancreatic Cancer
Study: NCT06539741
Drug: OxyCODONE 5 mg Oral Tablet
Normalized name: oxyCODONE 5 mg oral tablet
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5 mg by mouth every 6 hours as needed for pain
Study: NCT04899115
Drug: VE303
Normalized name: VE303
DrugBank: VE303 (DB17794)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting the last day of oral vancomycin (Day 1), subjects randomized to this arm will take 5 capsules of VE303 taken daily for 14 days.~The quantity of each strain is proportioned to assure a specific per-strain per-capsule titer. The 8 strains are blended together with a micro-crystalline cellulose flow agent and placed in enteric capsules.
Study: NCT04899115
Drug: oral vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All enrolled subjects will receive 5 days of oral vancomycin 125 mg four times a day (q.i.d).
Study: NCT05524038
Drug: Bupivacaine Hydrochloride
Normalized name: Bupivacaine Hydrochloride
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20mg of Bupivacaine hydrochloride as local anesthetic will be used in (QL) group and (ESB) group
Study: NCT05524038
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: injection of 4mg dexamethasone in each block
Study: NCT06522373
Drug: MT-0169
Normalized name: MT-0169
DrugBank: MT-0169 (DB17430)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given by Vein (IV)
Study: NCT05625087
Drug: Alpelisib
Normalized name: ALPELISIB
DrugBank: Alpelisib (DB12015)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alpelisib 300 mg once daily + fulvestrant 500 mg every 28 days
Study: NCT05625087
Drug: Ribociclib
Normalized name: Ribociclib
DrugBank: Ribociclib (DB11730)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ribocilcib 600 mg once daily 3 weeks on/1 week off + fulvestrant 500 mg every 28 days
Study: NCT05646862
Drug: Inavolisib
Normalized name: Inavolisib
DrugBank: Inavolisib (DB15275)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be administered a 9 milligram (mg) inavolisib tablet orally once a day (PO QD) on Days 1-28 of each 28-day cycle.
Study: NCT05646862
Drug: Fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will be administered 500 mg of fulvestrant on Days 1 and 15 of Cycle 1 and then on Day 1 of each subsequent 28-day cycle.
Study: NCT05646862
Drug: Alpelisib
Normalized name: ALPELISIB
DrugBank: Alpelisib (DB12015)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alpelisib will be administered to participants at the approved dose in combination with fulvestrant: 300 mg taken PO QD and on days 1-28 of each 28-day cycle.
Study: NCT04690673
Drug: Paracetamol
Normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 g oral paractamol
Study: NCT06081894
Drug: Aficamten
Normalized name: Aficamten
DrugBank: Aficamten (DB18490)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Tablet
Study: NCT06679855
Drug: Milrinone infusion
Normalized name: Milrinone
DrugBank: Milrinone (DB00235)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: An intravenous (iv) infusion of milrinone will be administered at an initial dose of 0.33 mcg/kg/min and accompanied by an iv bolus of 10 mL/kg of 0.9% NaCl (administered over 60 minutes).
Study: NCT04975334
Drug: Naloxone
Normalized name: Naloxone
DrugBank: Naloxone (DB01183)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One bolus and one infusion of naloxone
Study: NCT06295770
Drug: Obinutuzumab
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Obinutuzumab 1g IV on day one and 1 g IV on day 15, followed by identical course at month 6.
Study: NCT06369714
Drug: Concerta
Normalized name: Concerta
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate Hydrochloride Extended-Release Tablets with the following specifications: 18mg dosage, oral administration, once a day for a duration of 8 weeks.
Study: NCT06782932
Drug: Balstilimab
Normalized name: Balstilimab
DrugBank: Balstilimab (DB15676)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. 450 mg will be administered as a 30 minute IV Infusion (-5/+15 min) on day 1 of each cycle for a total of 6 cycles of treatment. Cycle 1 (14 days) is prior to surgical resection, Cycle 2 (14 days) is after surgery and prior to standard of care chemotherapy, and Cycles 3-6 (21 days) are given after completion of chemotherapy.~2. Drug: 450 mg IV
Study: NCT06782932
Drug: GVAX
Normalized name: GVAX
DrugBank: GVAX (DB17276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Vaccine (5 × 108 cells) will be administered on Day 2 of each cycle for a total of 6 cycles of treatment. Six intradermal injections will be given in the upper thighs and non-dominant arms. Cycle 1 (14 days) is prior to surgical resection, Cycle 2 (14 days) is after surgery and prior to standard of care chemotherapy, and Cycles 3-6 (21 days) are given after completion of chemotherapy.~2. Drug: GVAX
Study: NCT06782932
Drug: Balstilimab
Normalized name: Balstilimab
DrugBank: Balstilimab (DB15676)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. 450 mg will be administered as a 30 minute IV. Infusion (-5/+15 min) on day 1 of each cycle for a total of 6 cycles of treatment. Cycle 1 (14 days) is prior to surgical resection, Cycle 2 (14 days) is after surgery and prior to standard of care chemotherapy, and Cycles 3-6 (21 days) are given after completion of chemotherapy.~2. Drug: 450 mg IV
Study: NCT04625647
Drug: Sotorasib
Normalized name: SOTORASIB
DrugBank: Sotorasib (DB15569)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT05199688
Drug: Satralizumab
Normalized name: SATRALIZUMAB
DrugBank: Satralizumab (DB15762)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive satralizumab treatment for a minimum of 48 weeks and then will have the opportunity to enter an optional satralizumab extension (OSE) period.
Study: NCT06332599
Drug: BQT
Normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: PPI（esomeprazole or vonoprazan) 20 mg twice daily, bismuth potassium citrate 600 mg (220 mg elemental bismuth) twice daily, tetracycline 500 mg four times a day, and metronidazole 400 mg four times a day
Study: NCT06190678
Drug: Pirtobrutinib
Normalized name: Pirtobrutinib
DrugBank: Pirtobrutinib (DB17472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT06525740
Drug: Hydromorphone
Normalized name: Hydromorphone
DrugBank: Hydromorphone (DB00327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IT
Study: NCT06525740
Drug: Methadone
Normalized name: Methadone
DrugBank: Methadone (DB00333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT05141006
Drug: BOTOX
Normalized name: Botox
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Injection into the bladder
Study: NCT05141006
Drug: Placebo for BOTOX
Normalized name: Botox
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Injection into the bladder
Study: NCT05632159
Drug: Mg sulphate
Normalized name: MG 217 Psoriasis
DrugBank: Glyceryl 1-oleate (DB13171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction of anesthesia will be done by injecting fentanyl 2 μg/kg, propofol1.5-2.5 mg/kg and atracurium 0.5 mg/kg for muscle relaxation. With extra administration of intraoperative Magnesium sulphate 30 mg /kg as loading dose over 10 min then 10 mg /kg/ has maintenance dose
Study: NCT05026593
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin will be administered after completion of Sintilimab by IV infusion to achieve an initial target AUC of 5 mg/mL/min on Day 1.
Study: NCT05026593
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 75 mg/m\^2 will be administered after completion of Sintilimab by IV infusion on Day 1.
Study: NCT05026593
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide 100 mg/m\^2 will be administered by IV infusion following carboplatin or cisplatin administration, during the induction phase on Day 1 through 3 of each cycle. On Days 2 and 3, patients will receive etoposide alone.
Study: NCT05026593
Drug: Sintilimab
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sintilimab 200 mg will be administered by IV infusion following IBI110 on Day 1 of each 21-day .
Study: NCT02080767
Drug: Tecovirimat
Normalized name: Tecovirimat
DrugBank: Tecovirimat (DB12020)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral tablet 600mg daily dose(three capsules, 200 mg/capsule)
Study: NCT05417646
Drug: Empagliflozin
Normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Single-dose, 25 mg, two hours before clamp
Study: NCT05704361
Drug: RO7121932 IV - SAD
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Part 1: Participants will receive a single dose of RO7121932 administered as IV infusion.
Study: NCT05704361
Drug: RO7121932 SC - SAD
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Part 2: Participants will receive a single dose of RO7121932 administered as SC injection.
Study: NCT06300944
Drug: saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A maintenance dose of saline is 0.2mg/kg/h and postoperative PCIA regimen was Sufentanil 2ug/kg, ondansetron 16mg, diluted with appropriate normal saline, a total of 100ml
Study: NCT06300944
Drug: Esketamine
Normalized name: ESKETAMINE
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: A maintenance dose of esketamine is 0.2mg/kg/h and postoperative PCIA regimen was Sufentanil 2ug/kg, ondanseetron 16mg, esketamine 0.75mg/kg, diluted with appropriate normal saline, a total of 100ml
Study: NCT04827953
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine 1000 mg/m2 IV on days 1, 8 and 15 (conventional chemotherapy).
Study: NCT04827953
Drug: Nab paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nab-Paclitaxel 125 mg/m2 IV on days 1, 8 and 15 (conventional chemotherapy).
Study: NCT04827953
Drug: Zalifrelimab
Normalized name: Zalifrelimab
DrugBank: Zalifrelimab (DB15632)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zalifrelimab administration each 6 weeks.
Study: NCT05641753
Drug: Evolocumab Cartridge
Normalized name: evolocumab Cartridge
DrugBank: Evolocumab (DB09303)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Injectable PCSK9 inhibitor.
Study: NCT05641753
Drug: Atorvastatin Calcium Tablets
Normalized name: Atorvastatin Calcium Tablets
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HMG-CoA reductase inhibitor for oral use.
Study: NCT05641753
Drug: Ezetimibe Tablets
Normalized name: Ezetimibe Tablets
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Will only be distributed to patients with statin intolerance; replacement for both Atorvastatin and Evolocumab. Inhibitor of intestinal cholesterol for oral use.
Study: NCT05641753
Drug: 18F-FDG
Normalized name: 18F-FDG
DrugBank: Fludeoxyglucose (18F) (DB09502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Optional procedure. Positron emission tomography (PET) and computed tomography (CT) imaging to assess vascular inflammation and related anatomy requires injection of the PET tracer 18F-FDG. 18F-FDG is an FDA-approved analogue of sugar, routinely used to evaluate elevated metabolism in tissues, including increased metabolism due to inflammatory cells. A standard dose of 7.0 mSv will be administered.
Study: NCT06795373
Drug: Ritlecitinib
Normalized name: Ritlecitinib
DrugBank: Ritlecitinib (DB14924)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily dose of 100mg of ritlecitinib taken orally for 12 weeks
Study: NCT06333691
Drug: Calcium Gluconate
Normalized name: Calcium Gluconate
DrugBank: Calcium gluconate (DB11126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: to compare the effectiveness of calcium gluconate, cabergoline and diosmin in preventing ovarian hyperstimulation syndrome in high-risk patient undergoing ICSI procedure.
Study: NCT06789796
Drug: Iparomlimab and Tuvonralimab (QL1706)
Normalized name: cytarabine and daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5mg/kg , every 3 weeks
Study: NCT06457919
Drug: Tinengotinib
Normalized name: Tinengotinib
DrugBank: Tinengotinib (DB17384)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinengotinib will be administered daily for 28-day cycles. A flat dose of 10 mg PO once daily.
Study: NCT06457919
Drug: abiraterone acetate with prednisone
Normalized name: Abiraterone Acetate
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Abiraterone acetate 1000 mg PO QD in combination with prednisone 5 mg PO once or twice daily (QD or BID)
Study: NCT06457919
Drug: Enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enzalutamide 160 mg PO QD
Study: NCT06701682
Drug: Cohort A: vilobelimab
DrugBank: Vilobelimab (DB16416)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as an IV formulation of 800 mg per dose and up to 6 doses (planned for Days 1, 2, 4, 8, 15, and 22, if participant is in hospital setting and deemed appropriate by the investigator)